Everfine Shanghai Ltd  

FABP Cardiac Infarction Rapid Test Kit
Heart diseases, including acute myocardial infarction (AMI), are the second leading cause of death all over the world.  Among patients with heart diseases, the number of cases of AMI and angina pectoris has increased sharply in recent years: it accounts for 40% of the death caused by heart disease.  In fact, AMI is the leading cause of death in the United States: 500,000 people die of AMI each year.
AMI occurs when coronary artery is obstructed by blood clot and fails to supply blood to the heart.  This obstruction results in inadequate flow of oxygen-and nutrient-rich blood, and consequently the rapid onset of damage or even death to the portion of the heart muscle.  The normal function of heart muscle requires high level of oxygen supply, so even brief interruption of blood flow can cause tissue death.
Several studies worldwide have shown that life-saving therapies are most beneficial in the early course of AMI.  According to previous investigation, about 1.1 million Americans encounter AMI annually, of which 50% occasions are fatal.  Moreover, approximately 20% of the death occurs before patients can reach the emergency room in hospitals for the treatment.  Therefore, early detection and early treatment of AMI have become the most critical and effective steps of lifesaving.
We develop a new diagnostic product, FABP (Fatty Acid Binding Protein) Cardiac Infarction Rapid Test Kit to meet the challenges of health care and needs of diagnosis market,